Orexin (Hypocretin) receptor agonists and antagonists for treatment of sleep disorders: Rationale for development and current status

CNS Drugs

Volumn 27, Issue 2, 2013, Pages 83-90

  Mieda, Michihiro ^a   Sakurai, Takeshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; ALMOREXANT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIAZEPAM; FILOREXANT; HYPNOTIC SEDATIVE AGENT; JNJ 10397049; LORAZEPAM; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; OXYBATE SODIUM; PLACEBO; PSYCHOSTIMULANT AGENT; SB 649868; SUVOREXANT; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM;

CATAPLEXY; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; HUMAN; INSOMNIA; MESOLIMBIC DOPAMINERGIC SYSTEM; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REM SLEEP; REVIEW; SLEEP; SLEEP DISORDER; SLEEP QUALITY; SLEEP WAKING CYCLE; UNSPECIFIED SIDE EFFECT; WAKEFULNESS;

EID: 84876932335     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0036-8     Document Type: Review

References (72)

1. Sakurai T, Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci. 2011;32(8):451-62.
2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-85.
3. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322-7.
4. Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA. 1999;96(2):748-53.
5. Nambu T, Sakurai T, Mizukami K, et al. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999;827(1-2):243-60.
6. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996- 10015.
7. van den Pol AN. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci. 1999;19(8):3171-82.
8. Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000;23(8):359-65.
9. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-74.
10. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435(1):6-25.
11. Mieda M, Hasegawa E, Kisanuki YY, et al. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci. 2011;31(17):6518-26.
12. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50(2 Suppl. 1):S16-22.
13. Zeitzer JM, Nishino S, Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol Sci. 2006;27(7):368-74.
14. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437-51.
15. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30(2):345-54.
16. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171-81.
17. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-76.
18. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553-62.
19. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991-7.
20. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology. 2005;65(8):1184-8.
21. Kadotani H, Faraco J, Mignot E. Genetic studies in the sleep disorder narcolepsy. Genome Res. 1998;8(5):427-34.
22. Nishino S, Okuro M, Kotorii N, et al. Hypocretin/orexin and narcolepsy: new basic and clinical insights. Acta Physiol (Oxf). 2010;198(3):209-22.
23. Espana RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep. 2011;34(7):845-58.
24. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci. 2002;3(8):591-605.
25. Horvath TL, Peyron C, Diano S, et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol. 1999;415(2):145-59.
26. Yamanaka A, Tsujino N, Funahashi H, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun. 2002;290(4):1237-45.
27. Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA. 1999;96(19):10911-6.
28. Adamantidis AR, Zhang F, Aravanis AM, et al. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature. 2007;450(7168):420-4.
29. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci. 2000;20(20):7760-5.
30. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA. 2001;98(17):9965-70.
31. Espana RA, Baldo BA, Kelley AE, et al. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience. 2001;106(4):699-715.
32. Xi MC, Morales FR, Chase MH. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 2001;901(1-2):259-64.
33. van den Pol AN, Ghosh PK, Liu RJ, et al. Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus. J Physiol. 2002;541(Pt 1):169-85.
34. Brown RE, Sergeeva O, Eriksson KS, et al. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology. 2001;40(3):457-9.
35. Liu RJ, van den Pol AN, Aghajanian GK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci. 2002;22(21):9453-64.
36. Bayer L, Eggermann E, Serafin M, et al. Orexins (hypocretins) directly excite tuberomammillary neurons. Eur J Neurosci. 2001;14(9):1571-5.
37. Eriksson KS, Sergeeva O, Brown RE, et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci. 2001;21(23):9273-9.
38. Burlet S, Tyler CJ, Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin/orexin peptides: implications for wakefulness and narcolepsy. J Neurosci. 2002;22(7):2862-72.
39. Eggermann E, Serafin M, Bayer L, et al. Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience. 2001;108(2):177-81.
40. Li Y, Gao XB, Sakurai T, et al. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron. 2002;36(6):1169-81.
41. Yamanaka A, Tabuchi S, Tsunematsu T, et al. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci. 2010;30(38):12642-52.
42. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 2005;25(28):6716-20.
43. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron. 2005;46(5):787-98.
44. Takahashi K, Lin JS, Sakai K. Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. Neuroscience. 2008;153:860-70.
45. Horvath TL, Gao XB. Input organization and plasticity of hypocretin neurons: possible clues to obesity's association with insomnia. Cell Metab. 2005;1(4):279-86.
46. Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA. 2004;101(13):4649-54.
47. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243-66.
48. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150-5.
49. Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010;87(5):593-600.
50. Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther. 2012;91(6):975-85.
51. Porter RA, Chan WN, Coulton S, et al. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg Med Chem Lett. 2001;11(14):1907-10.
52. Smart D, Sabido-David C, Brough SJ, et al. SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol. 2001;132(6):1179-82.
53. Langmead CJ, Jerman JC, Brough SJ, et al. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004;141(2):340-6.
54. Renzulli C, Nash M, Wright M, et al. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans. Drug Metab Dispos. 2011;39(2):215-27.
55. Bettica P, Squassante L, Groeger JA, et al. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology. 2012;37(5):1224-33.
56. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53(14):5320-32.
57. Winrow CJ, Gotter AL, Cox CD, et al. Pharmacological characterization of MK-6096: a dual orexin receptor antagonist for insomnia. Neuropharmacology. 2012;62(2):978-87.
58. Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther. 2009;330(1):142-51.
59. Morairty SR, Revel FG, Malherbe P, et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One. 2012;7(7):e39131.
60. Mochizuki T, Arrigoni E, Marcus JN, et al. Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci USA. 2011;108(11):4471-6.
61. Carter ME, Adamantidis A, Ohtsu H, et al. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci. 2009;29(35):10939-49.
62. Carter ME, Brill J, Bonnavion P, et al. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci USA. 2012;109(39):E2635-44.
63. Actelion. Actelion and GSK discontinue clinical development of almorexant (online). http://www1.actelion.com/en/our-company/news-and-events/index.page? newsId=1483135. Accessed 4 Dec 2012.
64. GlaxoSmithKline. To evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on subjects with primary insomnia [ClinicalTrials.gov identifier NCT00426816]. (online). http://clinicaltrials.gov. Accessed 4 Dec 2012.
65. Merck. Safety and efficacy study in primary insomnia patients-study B (4305-029) [ClinicalTrials.gov identifier NCT01097629]. US National Institutes of Health, ClinicalTrials.gov (online). http://www.clinicaltrials.gov. Accessed 4 Dec 2012.
66. Merck. Safety and efficacy study in primary insomnia patients-study A (4305-028) [ClinicalTrials.gov identifier NCT01097616]. US National Institutes of Health, ClinicalTrials.gov (online). http://www.clinicaltrials.gov. Accessed 4 Dec 2012.
67. Merck. Merck making news (online). http://www.merck.com/newsroom/news- release-archive/research-and-development/2012-0613.html. Accessed 4 Dec 2012.
68. Merck. Polysomnography study of MK6096 in patients with primary insomnia (6096-011) [ClinicalTrials.gov identifier NCT01021852]. US National Institutes of Health, ClinicalTrials.gov (online). http://www.clinicaltrials.gov. Accessed 4 Dec 2012.
69. Merck. A study of the safety and efficacy of MK-6096 for migraine prophylaxis in participants with episodic migraine (MK-6096-020) [ClinicalTrials.gov Identifier: NCT01513291]. US National Institutes of Health, ClinicalTrials.gov (online). http://www.clinicaltrials.gov. Accessed 4 Dec 2012.
70. Merck. Safety and efficacy of MK-6096 as adjunctive therapy in participants with major depressive disorder and partial response to antidepressant monotherapy (MK-6096-022 AM2) [ClinicalTrials.gov Identifier: NCT01554176]. US National Institutes of Health, ClinicalTrials.gov (online). http://www.clinicaltrials.gov. Accessed 4 Dec 2012.
71. Study to evaluate MK-6096 in the treatment of painful diabetic neuropathy (PDN) in adults (MK-6096-021 AM1) [ClinicalTrials.gov Identifier: NCT01564459] US National Institutes of Health, ClinicalTrials.gov (online). http://www.clinicaltrials.gov. Accessed 4 Dec 2012.
72. Merck. Merck making news (online). http://www.mercknewsroom.com/press- release/prescription-medicine-news/merck-announces-fda-acceptance-new-drug- application-suvorex.